Metformin, a first-line treatment for T2D, increases peripheral (including hepatic) insulin sensitivity, reduces hepatic glycogenesis, and increases glucose uptake and utilization of insulin-stimulated peripheral tissues in MASLD patients [131]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.